NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BMLL · data 2026-10-31
Bio Medica Laboratories Limited
In plain words
Price: 17.2% below its 52-week high of ₹181.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | 38.5% |
| Profit growth, 3 years (yearly) | 228.1% |
At a glance
ROE 57.1%, ROCE 48.5%: how much profit it earns on the money it uses.
Debt/equity 1.51, Profit growth 228.1% and sales growth 38.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (57.1%).
- Profit grew 228.1% a year over 3 years.
- High borrowing: debt/equity 1.51.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal
- 27 Oct 26Deal Bulk deal: OSWAL ENERGIES LIMITED bought ₹1.17 cr (net ₹0 cr) -0.2% next session
- 26 Oct 26Deal Bulk deal: OSWAL ENERGIES LIMITED bought ₹2.1 cr (net ₹0 cr) +3.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Bio Medica Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 1.51, meaning borrowings are larger than shareholders' equity.
What is the 52-week high and low of Bio Medica Laboratories Limited?
The 52-week high is ₹181 and the 52-week low is ₹101.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Limited | ₹149.95 | — | — | — | 57.1% | 48.5% | 1.51 | +34.8% |
| Medicamen Organics Ltd. | ₹26.5 | ₹39 cr | — | — | -13.7% | -15% | 0.5 | -24.6% |
| Medi-Caps Ltd. | ₹24.69 | ₹30 cr | — | — | -2.6% | -9.5% | 0 | -5.8% |
| Lasa Supergenerics Ltd. | ₹4.67 | ₹25 cr | — | — | -51.1% | -27% | 0.2 | -55.1% |
| Sunrest Lifescience Limited | ₹39.25 | ₹17 cr | 4.5 | 0.8 | 22.4% | 25.9% | 0.85 | -6.5% |
| Ortin Global Ltd | ₹13.35 | ₹10 cr | — | — | -46.1% | -46.3% | 0.81 | +18.7% |
Compare BMLL with MEDIORG in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BMLL in NSE Scanner →